Hematopoietik kök hücre transplantasyonunda CD34 (+) hücre seleksiyonu ve ayıklama

ARPACI, Fikret

Hematopoietik kök hücre transplantasyonunda CD34 (+) hücre seleksiyonu ve ayıklama

Fikret ARPACI (GATA Tıbbi Onkoloji Bilim Dalı, Ankara, Türkiye)

Gülhane Tıp Dergisi

0 0

Yıl: 2011 Cilt: 53 Sayı: 3 Sayfa Aralığı: 226 - 231 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Hematopoietik kök hücre transplantasyonunda CD34 (+) hücre seleksiyonu ve ayıklama

Öz:

Periferik kan kök hücreler otolog kök hücre naklinde kök hücre kaynağı olarak kemik iliğinin yerini almaktadır. Tümör kitlesi her ne kadar periferik kan kök hücre fraksiyonlarında kemik iliğinden daha az olsa da, modern araştırma yöntemleri tümör hücrelerini periferik kan kök hücre fraksiyonlarında ortaya koyabilir. Graft içindeki tümör hücreleri posttransplant dönemdeki nükslere katkıda bulunabilir. Periferik kan kök hücre fraksiyonlarını tümörden ayıklama işlemi negatif ya da pozitif seleksiyonla yapılabilir. CD34 pozitif seleksiyon, on beş yıldan beri otolog transplantasyonda graftın tümör hücrelerinden temizlenmesinde, allojeneik transplantasyonda T hücre deplesyonunda, gen tedavisinde progenitör hücrelerin saflaştırılmasında ve progenitör hücrelerin ex-vivo ekspansiyonunda başarıyla kullanılmaktadır.

Anahtar Kelime:

Konular: Biyoloji Hücre ve Doku Mühendisliği Hematoloji Biyoteknoloji ve Uygulamalı Mikrobiyoloji Hücre Biyolojisi

CD34 (+) hücre seleksiyonu ve ayıklama transplantation

Öz:

Peripheral blood stem cells have replaced bone marrow as the primary source for autologous stem cell transplantation. Although tumor burden appears to be lower in peripheral blood stem cell fractions than in the bone marrow, modern detection methods can detect the tumor cell present in peripheral blood stem cell fractions. Tumor cells in the graft may contribute to relapses in posttransplant period. Purging of peripheral blood stem cell fractions can be done either by negative or positive selection. CD34 positive selection has been successfully used to deplete tumor cells from grafts for autologous transplantation, to deplete T cells for allogeneic transplantation, to enrich progenitor cells for gene therapy and ex-vivo expansion strategies of progenitor cells for 15 years.

Anahtar Kelime:

Konular: Biyoloji Hücre ve Doku Mühendisliği Hematoloji Biyoteknoloji ve Uygulamalı Mikrobiyoloji Hücre Biyolojisi

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Franklin W, Shpall EJ, Archer P, et al. Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support. Breast Cancer Res Treat 1996; 41: 1-13.
2. Sharp JG, Kessinger A, Vaukhan WP, et al. Detection and clinical significance of minimal tumor cell contamination of peripheral stem cell harverts. Int Cell Cloning 1992; 10 (Suppl 1): 92.
3. Moss TJ. Sensitive detection of metastatic tumor cells in bone marrow. Prog Clin Biol Res 1994; 389: 567-577.
4. Pantel K, Schlimok G, Braun S, et al. Diferential expression of proliferation –associated molecules in individual micrometastatic carcinoma cell. J Nation Cancer Inst 1993, 85: 1419-1424.
5. Kleinman MB, Wiley EL, Guo M, et al. Immunohistochemical detection of breast cancer cells in paired peripheral blood progenitor cell specimens collected after cytokine or cyctokine and myelosupressive chemotherapy. Bone Marrow Transplant 1999; 23: 1297-1301.
6. Passos-Coelho, Ross AA, Kahn DJ, et al. Similar breast cancer cell contamination of single day peripheral blood progenitor cell collections in obtained after priming with hemapoietic growth factor alone of after cyclophosphamide followed by growth factor. J Clin Oncol 1996; 14: 2569-2575.
7. Riethmüller G, Holz E, Schlimok G, et al. Monoclonal antibody therapy for resected Dukes’ C colorectal cancer: seven year outcome of multicenter randomized trial. J Clin Oncol 1998; 16: 1788-1794.
8. Kahn DG, Prilutskaya M, Cooper B, et al. The relationship betwen the indicence of tumor contamination and number of phereses for stage IV breast cancer. Blood 1997; 90 (Suppl 1): abstr 2514.
9. Brenner MK, Rill DR, Moen RC, et al. Gene marking to trace origin of relaps after autologous bone marrow transplantation. Lancet 1993; 341: 85-86.
10. Deisseroth AB, Zu Z, Claxton D, et al.Genetic marking shows that Ph+ cell present in autologous transplants of chronic myelogeneus leukemia (CML) contribute to relapse after autologous bone marrow transplantation in CML. Blood 1994; 83: 4068-4076.
11. Fields KK, Elfenbein GJ, Trudeau WL, et al. Clinical significance of bone marrow transplantation metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol 1996; 14: 1868-1876.
12. Cooper SW, Moss TJ, Ross MA, et al. Occult tumor contamination of hematopoietic stem-cell products dose not effect clinical outcome of autologous transplantation in patients with metastatic breast cancer. J Clin Oncol 1998; 16: 3509-3517.
13. Gribben JG, Freedman AS, Neuberk D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991; 325: 1525-1533.
14. Gorin NC, Aegerter P, Auvert B, et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: A European survey of the role of marrow purging. Blood 1990; 75: 1606-1614.
15. Gribben JG. Antibody-mediated purging. In: Thomas ED, Blume KG, Forma SJ (eds). Hematopoietic Cell Transplantation. 2nd ed. Blackwell Science Inc, 2004: 244-253.
16. Krause DS, Fackler MJ, Civin CJ. Stratord MW. CD34: structure, biology and clinical utility. Blood 1996; 87: 1-13.
17. Siena S, Bregni, M, Gianni M. Estimation of peripheral blood CD34+ cells for autologous transplantation in cancer patients. Exp Hematol 1993; 21: 203.
18. Isola L, Skerret D, Lipton J, et al. Haplo mismatch allogeneic BMT using CD34+ selected bone marrow cells. Blood 1997; 90 (Suppl 1): 342b.
19. Nieto Y, Shpall EJ. CD34+ blood stem cell transplantation. In: Reiffers J, Goldman J, Armitage JO (eds). Blood Stem Cell Transplantation. London: Martin Dunitz Ltd, 1998: 187-201.
20. Miltenyi S, Müller W, Weichel W, Radbruch A. Controllable T cell separation with MACS. Cytometry 1990; 11: 231-238.
21. Arpacı F, Gee A, Broulette M, et al. Controllable T cell depletion of marrow by high gradient magnetic separation. Exp Hematol 1996; 24: 626-628.
22. Müller A, Köhler A, Zinti F. CD34+ progenitör selection for allogenic transplantation. Experiences from the use of two different separation systems. Blood 1997; 90 (Suppl 1): 345b.
23. Handgretinger R, Lang P, Schumm M, et al. Isolation and transplantation of autologous peripheral CD34+ progenitör cells highly purified by magnetic activated cell sorting. Bone Marrow Transplant 1998; 21: 987-993.
24. Champlin R, Bail E, Holland K, et al. Importance of cell dose with CD34-selected autologos marrow transplant: Result of controlled trial. Blood 1995; 86: 293a.
25. Shpall EJ, Johns RB, Bearman SJ, et al. Transplantation of enriched CD34+ positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34- positive peripheral –blood progenitors and growt factors on engraftment. J Clin Oncol 1994; 12: 28-36.
26. Cornetta K, Sledge G, Yanovich S, et al. High dose chemotherapy and stem cell transplant in breast cancer: a randomized multicenter study of CD34 selection. Asco Proceedings. 2001; 20 (1): 17a (Abstract 66).
27. Billadeau D, Quam L, Thomas W, et al. Detection and quantitation of malignant cells in the peripheral blood multiple myeloma patients. Blood 1992; 80: 1818-1824.
28. Stewart Ak, Schiller G, Vescio R, et al. ASH Proceedings 1999; 714a (Abstract 3151).
29. Gorin NC, Lopez M, Laporte JP, et al. Preparation and successful engraftment of purified CD34+ bone marrow progenitör cells in patients with non-Hodgkin’s lymphoma. Blood 1995; 85: 1647-1654.
30. Berenson RJ, Anders RG, Bensinger WI, et al. Selection of CD34+ marrow cells for autologous marrow transplantation. In: Dicke KA, Spitzer G, Jagannath S, Evinger-Hodges MJ (eds). Autologous Bone Marrow Transplantation. Proceeding of the Fourth International Symposium. The University of Texas, MD Anderson Cancer Center, Boston: 1989: 55-60.
31. Appelhaum FR. Is purging stuck in purgatory. Oncology 1994; 8: 24-30.
32. Arpacı F, Öztürk B, Kömürcü Ş, et al. Isolation of peripheral CD34+ progenitor cells by high gradient immünomagnetic cell selection and autologous peripheral blood stem cell transplantation: Results of first pilot study in Turkey. Turk J Haemotol 1999; 16: 41-49.
33. Arpacı F, Çetin T, Ozet A, et al. The excessive numbers of total nucleated cells does not affect the performance of the CliniMACS. J Clin Apheresis 2004; 13: 197-201
34. Yalman N, Bilgen H, Anak S, et al. Haploidentical peripheral blood stem cell transplantation for infantile malignant osteopetrosis. Turk J Immunol 2000; 5: 9-12.
35. Balcı YI, Akdemir Y, Gumruk F, et al. CD-34 selected hematopoietic stem cell transplantation from HLA identical family members for Fanconi anemia. Pediatr Blood Cancer 2008; 50: 1065-1067.
36. Arpacı F, Tezcan İ, Kuzhan O, et al. G-CSF-mobilized haploidentical peripheral blood stem cell transplantation in children with poor prognostic nonmalignant disorders. Am J Hematol 2008; 83: 133-136.
37. Arpacı F. Periferik kan kök hücre transplantasyonunda “Purging” uygulama teknikleri ve klinik önemi. Hematoloji – Onkoloji 2000; 2: 133-138.
38. Arpacı F. Aferez ürünü ve hücreden arındırma. Türkiye Klinikleri J Int Med Sci 2005; 1: 82-85.

APA	ARPACI F (2011). Hematopoietik kök hücre transplantasyonunda CD34 (+) hücre seleksiyonu ve ayıklama. , 226 - 231.
Chicago	ARPACI Fikret Hematopoietik kök hücre transplantasyonunda CD34 (+) hücre seleksiyonu ve ayıklama. (2011): 226 - 231.
MLA	ARPACI Fikret Hematopoietik kök hücre transplantasyonunda CD34 (+) hücre seleksiyonu ve ayıklama. , 2011, ss.226 - 231.
AMA	ARPACI F Hematopoietik kök hücre transplantasyonunda CD34 (+) hücre seleksiyonu ve ayıklama. . 2011; 226 - 231.
Vancouver	ARPACI F Hematopoietik kök hücre transplantasyonunda CD34 (+) hücre seleksiyonu ve ayıklama. . 2011; 226 - 231.
IEEE	ARPACI F "Hematopoietik kök hücre transplantasyonunda CD34 (+) hücre seleksiyonu ve ayıklama." , ss.226 - 231, 2011.
ISNAD	ARPACI, Fikret. "Hematopoietik kök hücre transplantasyonunda CD34 (+) hücre seleksiyonu ve ayıklama". (2011), 226-231.

APA	ARPACI F (2011). Hematopoietik kök hücre transplantasyonunda CD34 (+) hücre seleksiyonu ve ayıklama. Gülhane Tıp Dergisi, 53(3), 226 - 231.
Chicago	ARPACI Fikret Hematopoietik kök hücre transplantasyonunda CD34 (+) hücre seleksiyonu ve ayıklama. Gülhane Tıp Dergisi 53, no.3 (2011): 226 - 231.
MLA	ARPACI Fikret Hematopoietik kök hücre transplantasyonunda CD34 (+) hücre seleksiyonu ve ayıklama. Gülhane Tıp Dergisi, vol.53, no.3, 2011, ss.226 - 231.
AMA	ARPACI F Hematopoietik kök hücre transplantasyonunda CD34 (+) hücre seleksiyonu ve ayıklama. Gülhane Tıp Dergisi. 2011; 53(3): 226 - 231.
Vancouver	ARPACI F Hematopoietik kök hücre transplantasyonunda CD34 (+) hücre seleksiyonu ve ayıklama. Gülhane Tıp Dergisi. 2011; 53(3): 226 - 231.
IEEE	ARPACI F "Hematopoietik kök hücre transplantasyonunda CD34 (+) hücre seleksiyonu ve ayıklama." Gülhane Tıp Dergisi, 53, ss.226 - 231, 2011.
ISNAD	ARPACI, Fikret. "Hematopoietik kök hücre transplantasyonunda CD34 (+) hücre seleksiyonu ve ayıklama". Gülhane Tıp Dergisi 53/3 (2011), 226-231.